Jordyn Liebman

Jordyn is an associate practicing in the areas of class actions and medical negligence litigation.

She summered and articled with Siskinds prior to her call to the Bar in 2023.

Jordyn has a strong interest in health law. Prior to entering law school, Jordyn obtained her Bachelor of Science in Nursing from the University of Windsor, where she graduated with Great Distinction and made the President’s Honour Roll. As a nursing student, Jordyn worked in the legal affairs and patient relations department of an acute care setting. She also was a Research Assistant for a study investigating palliative care and Medical Assistance in Dying. While pursuing her legal education at Western Law, Jordyn worked as a Registered Nurse in infection control/health records and as part of a mass vaccination centre during the COVID-19 vaccination roll-out. Jordyn was actively involved in the student legal clinic and projects with Pro Bono Students Canada. She won first place in the 2020 Legate Medical Malpractice Moot.

Jordyn enjoys playing ultimate frisbee and spending time with her family and schnoodle, Lando.

Board Member for TVCC (formerly Thames Valley Children’s Centre).
Middlesex Law Association, Member
College of Nurses of Ontario, Member 2020–2024

Jordyn has appeared in the following news articles, segments, and publications:

• November 3, 2023 - CTV News, "Proposed class action lawsuit alleges Ozempic maker failed to disclose serious side effects," written by Alexandra Mae Jones. Jordyn addresses Siskinds LLP's proposed class action lawsuit against Novo Nordisk, the manufacturer of Ozempic, Rybelsus, and Wegovy, and individuals affected by Ozempic's side effects.
• March 27, 2025 - AFR Magazine, "How Ozempic and other GLP-1s are transforming much more than just waistlines," written by Euan Black, Eugenie Kelly, Lauren Sams, Matthew Drummond, Maxim Boon, Michael Smith, Rachael Bolton and Sam Bennett. Jordyn addresses the responsibility of drug manufacturers to stay informed about the science and experiences of individuals on GLP-1 medications once they are on the market, and the scale of a class action like this.

• Class action settlements and notice
• Brain Cancer Awareness Day
• Study shows half of patients consuming pentosan polysulfate sodium unaware of drug’s harmful effects
• Suboxone tooth decay lawsuits on the rise in North America
• US Bard PowerPort litigation heating up
• Class Action pursued for Canadians alleging harms from Ozempic, semaglutide drugs
• Bard PowerPort Catheters: Device failures linked to health risks
• Are we there yet? Solidifying the U.S. – E.U. privacy landscape with President Biden’s new Executive Order